Processing...
Clinical Trials for Prostate Cancer
Search
Search
There are 220 active trials for advanced/metastatic prostate cancer.
Click on a trial to see more information.
220 trials meet filter criteria.
Sort by:
HealthScout AI summary: Adults with PSMA-positive metastatic castration-resistant prostate cancer after ARSI/CYP17 inhibitor and typically 1–2 taxanes receive intravenous [225Ac]Ac-FL-020, a PSMA-targeted alpha-emitting radiopharmaceutical delivering actinium-225 to induce DNA double-strand breaks. Single-arm dose-escalation/expansion assesses safety, PK/dosimetry (with [111In]In-FL-020 in a subset), and preliminary activity.
ClinicalTrials.gov ID: NCT06492122
HealthScout AI summary: Adults with PSMA-PET–positive metastatic castration‑resistant prostate adenocarcinoma (ECOG 0–1) after at least one novel androgen‑axis therapy and taxane exposure per cohort (including a cohort post–177Lu‑PSMA) receive IV 225Ac‑PSMA‑Trillium every 6 weeks up to 4 cycles. 225Ac‑PSMA‑Trillium is a PSMA-targeted small‑molecule alpha radioligand (actinium‑225, macropa chelator with albumin‑binding moiety) designed to enhance tumor uptake and limit salivary exposure by delivering alpha radiation–mediated DNA damage.
ClinicalTrials.gov ID: NCT06217822
HealthScout AI summary: Adults with metastatic castration-resistant prostate cancer who have progressed on or are intolerant to at least one next-generation hormonal agent and taxane receive ACE-232, an oral non-steroidal CYP11A1 inhibitor that suppresses steroidogenesis to reduce AR signaling. Single-arm, dose-escalation and dose-optimization cohorts are included, with a biomarker-enriched Phase 1B focusing on patients with AR gene alterations.
ClinicalTrials.gov ID: NCT06801236
HealthScout AI summary: Adults with metastatic castration-resistant prostate adenocarcinoma after at least one novel AR-targeted therapy and 1–2 taxane regimens (ECOG 0–1) receive GSK5458514, a PSMA×CD3 bispecific T‑cell engager redirecting T‑cell cytotoxicity to PSMA-expressing tumors, as monotherapy with possible combination cohorts. Excludes neuroendocrine variants, CNS metastases, prior PSMA CAR‑T/engagers, recent extensive PSMA radioligand therapy, significant autoimmune disease, or active viral hepatitis.
ClinicalTrials.gov ID: NCT06990880
Phase 1/2 Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
HealthScout AI summary: Eligible adult men with progressive mCRPC on continuous ADT after prior systemic therapy (ECOG 0–1) receive oral HLD‑0915 monotherapy in 21‑day cycles. HLD‑0915 is a first‑in‑class RIPTAC small molecule that leverages androgen receptor as a tumor handle to recruit BRD4 (AR–BRD4 RIPTAC), inducing selective cancer cell death; exclusions include neuroendocrine/small‑cell features and significant bleeding or cardiac disease.
ClinicalTrials.gov ID: NCT06800313
HealthScout AI summary: Men with localized, histologically confirmed intraprostatic recurrence after prior external-beam or HDR brachytherapy (ECOG 0–1, no nodal/metastatic disease) undergo interstitial photodynamic therapy using the SpectraCure P18 laser with IDOSE planning plus verteporfin. Verteporfin is a benzoporphyrin photosensitizer that accumulates in tumor/neovasculature and, when light-activated, generates reactive oxygen species to induce vascular shutdown and tumor necrosis; patients unsuitable for salvage surgery or curative re-irradiation are eligible.
ClinicalTrials.gov ID: NCT03067051
HealthScout AI summary: Adults with metastatic castration-resistant prostate cancer (adenocarcinoma or neuroendocrine variants), ECOG 0–1, are enrolled to receive a STEAP2-targeted theranostic: imaging with radiolabeled AZD2287 (± cold antibody AZD2275 pre-dose) followed by dose-escalated [225Ac]-AZD2284, an actinium-225–labeled anti-STEAP2 monoclonal antibody delivering alpha radiation to STEAP2-expressing tumors. Key exclusions include recent radiopharmaceuticals/therapy and significant comorbidities; outcomes focus on safety, dosimetry, biodistribution, and preliminary antitumor activity.
ClinicalTrials.gov ID: NCT06879041
HealthScout AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.
ClinicalTrials.gov ID: NCT06910657
HealthScout AI summary: Adults with advanced/metastatic solid tumors who have exhausted standard options receive IV TJ101, a bispecific EGFR/B7-H3 antibody–drug conjugate, every 3 weeks in dose escalation with biomarker-driven expansion cohorts. Excludes prior topoisomerase I inhibitor or TOP1i-ADC exposure, active ILD/pneumonitis, significant ocular or uncontrolled cardiovascular disease, and active CNS disease unless treated and stable.
ClinicalTrials.gov ID: NCT07181473
HealthScout AI summary: Enrolling adult men with progressive mCRPC (ECOG 0–1) after ≥1 ARPI and either prior taxane or appropriate to defer taxane, requiring PSMA-avid disease on PSMA-PET and adequate organ function; includes both 177Lu-PSMA–naïve and –experienced cohorts. Patients receive AB001 (212Pb‑NG001), a PSMA-targeted alpha radioligand delivering short–path length high-LET radiation via 212Pb decay, given IV every 6 weeks for up to 4–6 cycles with dose/schedule optimization based on safety and preliminary activity.
ClinicalTrials.gov ID: NCT07214961